Published TCIMAIL newest issue No.201
Maximum quantity allowed is 999
CAS RN: 68047-06-3 | Product Number: H1693
(Z)-4-Hydroxytamoxifen
Purity: >95.0%(HPLC)
- (Z)-4-[1-[4-[2-(Dimethylamino)ethoxy]phenyl]-2-phenylbut-1-en-1-yl]phenol
- 4-[(1Z)-1-[4-[2-(Dimethylamino)ethoxy]phenyl]-2-phenyl-1-buten-1-yl]phenol
* Stock available in Belgium: Shipment on the same day
* Stock available in Japan: Please check the Shipping Simulation for estimated shipments. (excludes regulated items and dry ice shipments)
| Product Number | H1693 |
Purity / Analysis Method
|
>95.0%(HPLC) |
| Molecular Formula / Molecular Weight | C__2__6H__2__9NO__2 = 387.52 |
| Physical State (20 deg.C) | Solid |
Storage Temperature
|
Frozen (<0°C) |
| Store Under Inert Gas | Store under inert gas |
| Condition to Avoid | Air Sensitive,Hygroscopic,Heat Sensitive |
| CAS RN | 68047-06-3 |
| Reaxys Registry Number | 4910748 |
| MDL Number | MFCD00468090 |
| Appearance | White to Light yellow powder to crystal |
| Purity(HPLC) | min. 95.0 area% |
| Melting point | 152.0 to 156.0 °C |
| NMR | confirm to structure |
| Melting Point | 154 °C |
| Pictogram |
|
| Signal Word | Danger |
| Hazard Statements | H302 : Harmful if swallowed. H360 : May damage fertility or the unborn child. H362 : May cause harm to breast-fed children. H350 : May cause cancer. |
| Precautionary Statements | P263 : Avoid contact during pregnancy and while nursing. P260 : Do not breathe dust. P202 : Do not handle until all safety precautions have been read and understood. P201 : Obtain special instructions before use. P280 : Wear protective gloves/ protective clothing/ eye protection/ face protection/ hearing protection. P308 + P313 : IF exposed or concerned: Get medical advice/ attention. |
| RTECS# | SL1210000 |
| HS Number | 2922190090 |
References
- Variable contribution of cytochromes P450 2D6, 2C9 and 3A4 to the 4-hydroxylation of tamoxifen by human liver microsomes
- Coactivator and corepressor regulation of the agonist/antagonist activity of the mixed antiestrogen, 4-hydroxytamoxifen
- Oxidative metabolism of tamoxifen to Z-4-hydroxytamoxifen hydroxytamoxifen by cytochrome P450 isoforms: An appraisal of in vitro studies (a review)
- Targeting of tamoxifen to enhance antitumour action for the treatment and prevention of breast cancer: The ‘personalised’ approach?
References
- Small molecule-triggered Cas9 protein with improved genome-editing specificity
- Profiling of engineering hotspots identifies an allosteric CRISPR-Cas9 switch
- Multimode drug inducible CRISPR/Cas9 devices for transcriptional activation and genome editing
- HIT-Cas9: A CRISPR/Cas9 Genome-Editing Device under Tight and Effective Drug Control
Safety Data Sheet (SDS)
The requested SDS is not available.
Please Contact Us for more information.
The requested SDS is not available.
Specifications
The requested specifications are not available.
Please Contact Us for more information.
The requested specifications are not available.
C of A & Other Certificates
Please check that the lot number you have entered is correct. It is 4-5 alphanumeric characters before the hyphen. In particular, please check O (letter) or 0 (number) and I (letter) or 1 (number).
If your information is correct and you are still not able to view the requested certificates, Please Contact Us for more information.
Please check that the lot number you have entered is correct. It is 7 alphanumeric characters. In particular, please check O (letter) or 0 (number) and I (letter) or 1 (number).
Sample C of A
A sample C of A for this product is not available at this time.
Analytical Charts
The requested analytical chart is not available. Sorry for the inconvenience.